Optimization of solubility studies performed in the context of BCS biowaiver monographs [PDF]
Die vorliegende Dissertation stellt eine Methode zur Löslichkeitsbestimmung vor, die für die Anwendung im Rahmen von BCS-Biowaiver Monografien entwickelt wurde.
Plöger, Gerlinde Friederike
core +2 more sources
Evaluation of Excipient Risk in BCS Class I and III Biowaivers. [PDF]
Abstract The objective of this review article is to summarize literature data pertinent to potential excipient effects on intestinal drug permeability and transit. Despite the use of excipients in drug products for decades, considerable research efforts have been directed towards evaluating their potential effects
Metry M, Polli JE.
europepmc +5 more sources
INRODUCTION. Biowaiver procedure based on the biopharmaceutics classification system (BCS) is widely used in regulatory practice when assessing the bioequivalence of generic medicinal products (GMPs).
N. J. Dahma +5 more
doaj +2 more sources
This analysis studies the pharmaceutical approval policy regarding generics in the United States and European and Indian markets. Therapeutically equivalent generics are therefore considered safe, effective, and of comparable quality to their name‐brand counterparts.
Rakan Alsaqer +10 more
wiley +2 more sources
Challenges obtaining a biowaiver for topical veterinary dosage forms [PDF]
Baynes, R., Riviere, J., Franz, T., Monteiro‐Riviere, N., Lehman, P., Peyrou, M., Toutain, P.‐L. Challenges obtaining a biowaiver for topical veterinary dosage forms.J. vet. Pharmacol. Therap.35(Suppl. 1), 103–114.Obtaining a biowaiver for topical drugs used in veterinary species faces many of the same challenges associated with human topicals. However,
Baynes, Ronald E +6 more
openaire +6 more sources
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisone [PDF]
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisone are reviewed. Due to insufficient data prednisone cannot be definitively classified according to the current Biopharmaceutics Classification System (BCS) criteria as ...
Vogt, M +8 more
openaire +8 more sources
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report [PDF]
This report summarizes the proceedings for day 2 sessions 1 and 3 of the 2‐day public workshop entitled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” a jointly sponsored workshop by the US Food and Drug ...
Fang Wu +17 more
doaj +2 more sources
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate [PDF]
S.2-13Sitagliptin is an antihyperglycemic drug used in adults for the treatment of diabetes Type 2. Literature data and in-house experiments were applied in this monograph to assess whether methods based on the Biopharmaceutics Classification System (BCS)
Mehta, M. +13 more
core +2 more sources
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fexofenadine [PDF]
29812993In this monograph, the potential use of methods based on the Biopharmaceutics Classification System (BCS) framework to evaluate the bioequivalence of solid immediate-release (IR) oral dosage forms containing fexofenadine hydrochloride as a ...
Langguth, Peter +11 more
core +2 more sources
Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant [PDF]
Lemborexant is a dual orexin receptor antagonist assigned to class II of the Biopharmaceutics Classification System (BCS). Thus, the ICH M9 Guideline excludes immediate-release (IR) solid oral dosage forms containing lemborexant from BCS-based biowaivers, irrespective of their in vitro dissolution behavior.
Beran, Kristian +11 more
openaire +4 more sources

